fda_tracker Posted - 11 hours ago

$ALVO Phase 3 trial w/est May completion date NCT05986786: https://www.clinicaltrials.gov/study/NCT05986786 Trial Tracker: https://www.fdatracker.com/trial-tracker/

Stock_Titan Posted - 13 hours ago

$ALVO Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 https://www.stocktitan.net/news/ALVO/alvotech-announces-participation-at-bof-a-securities-healthcare-6qxhysxxjhrj.html

Stock_Titan Posted - 04/30/24

$ALVO U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) https://www.stocktitan.net/news/ALVO/u-s-commercialization-agreement-with-quallent-to-drive-patient-5606ijvedi63.html

Stock_Titan Posted - 04/24/24

$ALVO Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) https://www.stocktitan.net/news/ALVO/alvotech-announces-topline-results-from-a-confirmatory-clinical-uqtvdpva54cl.html

tradingtwenty Posted - 04/19/24

$ALVO has trended 18 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 19, 2024 06:10 AM: Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar... Link: https://tradingtwenty.com/news/435173/alvotech-signs-us-agreement-to-expand-access-for-newly-approved-high-concentration-interchangeable-biosimilar-to-humira-adalimumab

Stocksrunner Posted - 04/19/24

📈 Power Hour on High Volume Stocks! $AULT secures $44M investment, spiking interest. $DMTK BTIG downgrade prompts trading surge. $SMCI earnings stir market activity. $NFLX Mixed news drives trading frenzy. $ALVO US agreement boosts trading volume.

hingfdiuh Posted - 04/19/24

Is $WBA the "unspecified company" that $ALVO has "signed a 'long-term agreement' with"? Keep in mind that the Alvotech drug has been excluded from the big three PBMs for 2024: CVS Caremark, OptumRx, and Express Scripts. Read below. Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version of AbbVie’s blockbuster drug Humira, Alvotech said Friday. The Alvotech spokesperson said the company would be making further statements on its partnership in about four weeks. https://www.biopharmadive.com/news/alvotech-teva-humira-biosimilar-partnership-sales-simlandi/713703/

Terrordomo80 Posted - 04/19/24

$TEVA Even $ALVO is now outperforming us.. Doc Jizzards be like...

Bornjever Posted - 04/19/24

$ALVO May I remind us all Humira has 21 billion in sales and still selling so we have big potential

DonCorleone77 Posted - 04/19/24

$ALVO $TEVA Alvotech signs agreement with Teva to bring Adalimumab-ryvk to U.S. market Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira. The current multi-product commercialization partnership between Teva Pharmaceuticals (TEVA) and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the Simland brand in the U.S.

Stock_Titan Posted - 04/19/24

$ALVO Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) https://www.stocktitan.net/news/ALVO/alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-vm3mwfgl1pw2.html

G101SPM Posted - 04/17/24

$TEVA $13.29 bid. DAC (dollar average cost) $12.00 (1.31.24). EXIT $19.00. NEWS: Teva Pharma and Alvotech ($ALVO) announce U.S. FDA approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab). ^SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva. ^SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara. ^SELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara. ^Sales of the reference product Stelara in the U.S. were nearly $7 billion in 2023.

Stocksrunner Posted - 04/16/24

$ALVO and $TEVA just scored a major win, as the FDA has approved their SELARSDI™ biosimilar to the blockbuster drug Stelara®. This is a huge development that will allow them to challenge the dominance of the original biologic and provide more affordable treatment options for patients. Investors are sure to be buzzing about the potential impact on Alvotech and Teva's bottom lines moving forward. 💰

RiskVsReward Posted - 04/16/24

Watch $ALVO closely (Dont blink)

tradingtwenty Posted - 04/16/24

$ALVO has trended 33 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 16, 2024 05:43 PM: Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) Link: https://tradingtwenty.com/news/431531/alvotech-and-teva-announce-us-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-stelara-ustekinumab

tradingtwenty Posted - 04/16/24

Top 5 after-hours stocks that have trended in the past 24 hours: $INVO 81.57% 🔥 $CLNN 45.52% $CXAI 22.76% $ALVO 13.04% $PALI 6.91% Link: https://tradingtwenty.com/dashboard/trending/past

UBER_ONE Posted - 04/16/24

$ALVO $INVO

DonCorleone77 Posted - 04/16/24

$TEVA $ALVO Teva and Alvotech announce FDA approved SELARSDI injection Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) announced that the FDA has approved SELARSDI, or ustekinumab-aekn, injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the U.S. Ustekinumab is a human monoclonal antibody (mAb) that selectively targets the p40 protein, a component common to both interleukin-12 and IL-23 cytokines, which play crucial roles in treating immune-mediated diseases like psoriasis and psoriatic arthritis. Alvotech developed and produces SELARSDI using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara. Sales of the reference product Stelara in the U.S. were nearly $7B in 2023.

UBER_ONE Posted - 04/16/24

$ALVO

Stock_Titan Posted - 04/16/24

$ALVO Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) https://www.stocktitan.net/news/ALVO/alvotech-and-teva-announce-u-s-fda-approval-of-selarsdi-ustekinumab-wt0mebtkleua.html

TradeHawk Posted - 04/16/24

$ALVO $TEVA Alvotech and Teva Pharmaceutical get FDA approval of Selarsdi, a biosimilar of Johnson & Johnsons blockbuster immunology drug Stelara. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761343

pcguy2 Posted - 04/16/24

$ALVO No PR on PDUFA date? bad sign..... Not that there is anyone on this board LOL

pcguy2 Posted - 04/11/24

$ALVO PDUFA date of AVT-004 (Stelara) is April 16, 2024

Bornjever Posted - 04/05/24

$ALVO I am studying as much as I can and I just found out that HUMIRA exclusive patent expired in 2023 and we just had our equal to this monster drug approved and our stock price went down but I just found out that they have sold 20 billion plus of this drug and we are for sure going to sell billions before we are done and next drug we are working on development is KEYTRUDA and I am buying more shares because we are not going to just be a small player.

DonCorleone77 Posted - 04/03/24

$ALVO Alvotech selloff brings 'unique buying opportunity,' says Northland Northland views the recent pullback in shares of Alvotech as a "unique buying opportunity." The analyst sees several near-term catalysts for the sock, including the announcements of major healthcare payer contracts for Simlandi, FDA approval of AVT04, a Stelara biosimilar, in mid-April, and submission three biologics license applications in fiscal 2024. The firm sees Alvotech emerging as a global leader in the biosimilars segment with a "vast pipeline" that addresses reference product sales with peak sales of $100B. The stock remains a top pick at Northland with a $28 price target.

Stock_Titan Posted - 04/03/24

$ALVO Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 https://www.stocktitan.net/news/ALVO/alvotech-hosts-audio-call-for-investors-at-8-15-am-edt-on-april-3-t2lf5163bk6p.html

Bornjever Posted - 1 month ago

$ALVO just did some research and my sight never registered last quarter earnings so new info for me is first quarter of 2024 is 5-17 and hope better earnings with better price as I know this will be a gold mine but as usual in bio taking longer to get to where the gold is. Still

pcguy2 Posted - 03/27/24

$ALVO major milestones this year including 1 approval (April) 3 submissions (2nd half), and 2 clinical trial data (2Q)

Bornjever Posted - 03/27/24

$ALVO we will see each quarter get better and better sales and profits increase each quarter with sales of Humira equal being added in a few months.

Bornjever Posted - 03/25/24

$ALVO this company focuses on bio similar drug manufacturing and current pipeline has 8 biosimilars with Humira being the one just approved and sales to begin in summer and just issued more shares to raise capital but Aztiq has 1.4 billion invested and Celtic Holdings has 1.3 billion invested